Announcements
- argenx Reports First Quarter 2024 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2024 Health Care Conference
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
- argenx Announces Annual General Meeting of Shareholders on May 7, 2024
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- argenx to Present at Upcoming Investor Conferences
More ▼
Key statistics
On Monday, argenx SE (A1RG34:SAO) closed at 73.36, 14.04% above the 52 week low of 64.33 set on Dec 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 73.36 |
---|---|
High | 73.36 |
Low | 73.36 |
Bid | 70.80 |
Offer | 80.02 |
Previous close | 73.36 |
Average volume | 1.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 20 2024 20:54 BST.
More ▼